x xc

Benjamin List: “Wow, this could be something big”

“Wow, this could be something big”

Asymmetric organic catalysis? Nobel Laureate Benjamin List explains how he came up with this crazy idea and what it means for our future at the 2026 GDNÄ conference in Bremen.

Professor List, in December 2021 you were awarded the Nobel Prize in Chemistry. Has your life changed since then?
Yes, it has – especially at the beginning. TV appearances weren’t part of my normal daily routine before. Nor were the many public lectures, whether at ‘Jugend forscht’, the Kulturhaus Heidelberg or in university lecture theatres. The first two or three years were very intense. In the meantime, I’ve been able to get my life back to normal and finally have enough time again for my large research group at the institute in Mülheim. It’s not as if, as a Nobel laureate, you stop doing research.

What are you currently working on?
I’d like to highlight two projects. Firstly, we’re trying to remove the greenhouse gas CO2 from the atmosphere by breaking it down into O2 and C using sunlight and catalysts. The oxygen O2 returns to the atmosphere without any issues; what remains is carbon. This could be used as a kind of solar coal for all sorts of processes in the chemical industry. Surplus coal could be buried, for example in tunnels along the Rhine and Ruhr. The whole thing could help solve humanity’s energy problem and would be climate-neutral at the same time. We’re still facing a few tricky problems, but hopefully they’ll be solved in ten years’ time. Our idea isn’t entirely far-fetched; after all, CO2 splitting is already taking place on Mars, albeit only in small quantities. 

And your second project?
We’re currently setting up a company that produces pure fragrances. At the molecular level, fragrances usually consist of two variants, known as enantiomers. They fit together like a picture and its mirror image, but have biologically different effects. The original might smell of mint, for example, and the mirror image of caraway – together they make a strange mixture. In industrial production, therefore, the aim is to produce pure fragrances containing only one of these molecular twins. To date, this has only been possible using complex processes. With the help of our patents, production can be simplified and made cheaper. I think we’ll be able to start this year. I am a basic researcher, but getting to know the industrial world is exciting.

 

© David Ausserhofer

At work: Benjamin List leads a team of around forty researchers from all over the world. Teamwork is a top priority in the List research group.

You were awarded the Nobel Prize for the discovery of asymmetric organic catalysis. What makes this process so significant?
Catalysis as such is very, very important for our lives. Just one example: without the Haber-Bosch process, that classic example of catalysis, there would be no fertilisers. We wouldn’t then be eight billion people, but perhaps only four billion due to a lack of sufficient food. I consider catalysis to be humanity’s most important technology.  Overall, there have already been several Nobel Prizes for catalysis research, and almost all of them were for metallic catalysts. Unfortunately, these also have drawbacks: many of them are expensive, rare and, on top of that, toxic. In 1999, I experimented with a small molecule, the amino acid proline, and discovered that it not only acts as a catalyst but also specifically produces the desired enantiomer. When I published this in early 2000, it came as a huge surprise to the scientific community: an organic molecule found in the human body acts as a highly selective catalyst – incredible! 

You share the Nobel Prize with the Scottish-born US researcher David MacMillan, who arrived at similar results independently of you. Was the discovery in the air?
In hindsight, you could see it that way. David and I actually knew nothing about each other. We each made the crucial discoveries independently in 1999. When my very first proline experiment worked, I thought: Wow, this could be something big. Yet the idea itself wasn’t actually that new. Other chemists had tried it too. When the initial experimental results from the 1960s and 1970s weren’t really understood, interest in it waned. David MacMillan and I then tried a different approach and succeeded. Many chemists at the time rubbed their eyes in disbelief and asked: How could we have overlooked this?

@ David Ausserhofer

A scene in the laboratory of Benjamin List’s ‘Homogeneous Catalysis’ department at the Max Planck Institute for Coal Research in Mülheim.

Is organocatalysis used in industry today?
Yes, in many fields, including the production of medicines. One example is darunavir for the treatment of HIV. The active ingredient, a so-called protease inhibitor, prevents the AIDS virus from multiplying in infected people. The World Health Organisation has included it on the list of essential medicines.

Is more public funding needed for catalysis research?
Yes, that would be money well spent. At present, we are lagging behind in artificial intelligence, quantum and fusion technologies, far behind the US and China. Catalysis is not as popular, but it represents a major opportunity for Germany. We have a long tradition in this field and a great deal of expertise in the country. 

Let’s take a look back: how did you come to become a chemist?
It all began when I was eleven years old. Together with two friends, I had set up a small laboratory in a basement in Frankfurt; we bought the necessary chemicals from a local chemist. At that time, I wasn’t yet taking chemistry lessons. Later, I had a few gifted teachers who encouraged me. But by then my interest in the subject was already very strong, and no teacher could have steered me away from that path. 

The GDNÄ has its own youth organisation, the jGDNÄ. Is there anything you would advise young people interested in the natural sciences?
Follow your passion! Don’t let yourselves be swayed, even if your parents say: ‘I see you as a lawyer or a doctor.’ There are good career opportunities in the natural sciences, both in academia and in industry. The world has recognised how important research is. And it’s a stroke of luck if you’re interested in it. It gives me immense pleasure to be able to unlock a few of nature’s secrets and perhaps change the world in the process. 

On 19 September, you will be giving the public Nobel lecture on the topic of ‘Organocatalysis for our world’ at the GDNÄ meeting in Bremen. What prior knowledge is needed to follow your talk?
An interest in the subject should suffice. I try to speak as clearly as possible. 

What message do you want to convey to your audience?
Organocatalysis can be both basic research and application. Both are fascinating, and that is what I want to convey. And in doing so, I’d also like to promote the Max Planck Society a little. Its outstanding basic research is well known to many, but not everyone realises that it is also the most successful start-up organisation in this country. I have one more message: enthusiasm for what you do is important. Whether in research or in other areas of life. 

To conclude, may I ask you about a particular photo showing you standing on your hands with your legs crossed in the laboratory? How did that come about?
The photo was taken a few years before the Nobel Prize, during an interview with my fellow student Catarina Pietschmann, who works as a freelance journalist in Berlin. ‘You have to swim against the tide now and then,’ I’d said during the conversation, ‘maybe even stand on your head.’ That’s how the idea for the handstand in the lotus position came about. My wife was in the lab at the time; she held me up. I can’t manage a handstand on my own just yet. 

Do you practise yoga?
Yes, yoga is important to me for keeping my mind fresh. I’ve been doing it for many years, one to two hours a day and mostly without instruction. I’ve got the hang of it a bit now.

Michael Droescher © MIKA-fotografie | Berlin

@ Henning Kretschmer

Prof. Dr. Dr. h.c. Dr. h.c. Benjamin List is Director of the Max Planck Institute for Coal Research and a Nobel Laureate in Chemistry.

About the person

Prof. Dr. Dr. h.c. Dr. h.c. Benjamin List is a chemist and one of the directors at the Max Planck Institute for Coal Research in Mülheim an der Ruhr. There he heads the Department of Homogeneous Catalysis. He is also a professor of organic chemistry at the Universities of Cologne and Hokkaido.

Benjamin List was born on 11 January 1968 in Frankfurt am Main. As the child of a family of scientists and artists, he spent his childhood and youth with his mother and two brothers. He completed his degree in chemistry at the Free University of Berlin in 1993. In Frankfurt am Main, he was awarded his doctorate in 1997 with a thesis on the synthesis of a vitamin B12 semicorrin. In 1997, Ben List, as many people call him, moved to the USA to conduct research at the Scripps Research Institute in La Jolla, California, until 2003. Back in Germany, he led a research group at the Max Planck Institute for Coal Research in Mülheim an der Ruhr from 2003 to 2005. He has worked there since 2005 as Director and a Scientific Member of the Max Planck Society.

Benjamin List has received numerous honours, including Germany’s highest research award, the Leibniz Prize. In 2021, he was awarded the Nobel Prize in Chemistry, jointly with David MacMillan, who is the same age, for the development of asymmetric organocatalysis. In 2022, the Federal President awarded him the Grand Cross of the Order of Merit of the Federal Republic of Germany with Star.

Michael Droescher © MIKA-fotografie | Berlin

@ Frank Vinken/MPG

A handstand in the lab: Benjamin List only does things like this for photographers. The photo was taken a few years before he won the Nobel Prize; he managed the pose with his wife’s help.

Further reading and listening

High honour for Katharina Kohse-Höinghaus

High honour for Katharina Kohse-Höinghaus

The physical chemist and GDNÄ group chair was awarded honorary membership of the Bunsen Society

At the annual meeting of the German Bunsen Society for Physical Chemistry, the 2026 Bunsen Conference in Dresden, Senior Professor Katharina Kohse-Höinghaus was awarded honorary membership in recognition of her services to the society. As Professor Melanie Schnell (DESY Hamburg and University of Kiel) emphasised in her laudatory speech, Kohse-Höinghaus is the first woman among the 58 honorary members to date in more than 130 years. The Bunsen Conference 2026 took place from 30 March to 1 April on the theme of ‘Properties and Processes under Confinement’.

 © DBG / Heike Kolossa

Ceremonial presentation: The President of the German Bunsen Society, Professor Robert Franke, presents Professor Katharina Kohse-Höinghaus with the honorary membership certificate.

According to the Society’s website, honorary membership has been awarded since 1894 for “pioneering, successful work of national and international distinction, for outstanding pioneers of physical-chemical science and technology, and in recognition of special services to the intellectual and material advancement of physical chemistry”. Renowned and influential scientists in physics and chemistry have been honoured in this way, including Robert Wilhelm Bunsen, Svante Arrhenius, Max Planck, Walther Nernst and Otto Hahn, as well as, more recently, Manfred Eigen, Gerhard Ertl and Stefan Hell.

Katharina Kohse-Höinghaus has been associated with the Bunsen Society in a prominent role for many years. Of particular note are her presidency in 2007 and 2008 (also as the first and so far only woman), her co-organisation of the Bunsen Conference in Bielefeld in 2010, the presentation of the Society’s Wilhelm Jost Memorial Lecture in conjunction with the Lower Saxony Academy in Göttingen in 2012, and her award of the Walther Nernst Commemorative Medal in 2020.

Honorary membership was conferred for the first time on 30 March, Robert Wilhelm Bunsen’s birthday. “I am delighted to have received this honour 50 years after my first attendance at a Bunsen Conference in 1976, when I was still a doctoral student,” says Katharina Kohse-Höinghaus.

Saarbrücken 2018 © Robertus Koppies

© Universität Bielefeld / Norma Langohr

Prof. Dr. Katharina Kohse-Höinghaus.

About the person

Katharina Kohse-Höinghaus is a senior professor of physical chemistry at Bielefeld University. The 74-year-old is internationally renowned for her work on the diagnosis of combustion processes using laser spectroscopy and mass spectrometry. From 1994 to 2017, she held a chair in Physical Chemistry at Bielefeld University. Prior to this, Kohse-Höinghaus conducted research at various institutions in Germany and abroad; in 1992, she obtained her habilitation with a thesis on energy technology at the University of Stuttgart. On the initiative of Katharina Kohse-Höinghaus, one of the first German hands-on laboratories, teutolab, was founded in 2000. There are now satellite laboratories in the Bielefeld region, across Europe and in Asia. The internationally renowned scientist is a member of several academies, including the Leopoldina and acatech, as well as numerous committees and scientific institutions in Germany and abroad. She has received many awards, including the Federal Cross of Merit on Ribbon, as well as honorary and visiting professorships in several countries. In 2007, she became the first woman to be elected President of the German Bunsen Society. Katharina Kohse-Höinghaus was the first European to serve as President of the International Combustion Institute from 2012 to 2016. She has been a member of the GDNÄ for many years and is one of the key contributors to the scientific conference programmes in the field of engineering sciences. At the 2026 GDNÄ Conference in Bremen, she will serve as group chair for the field of engineering sciences.

XLAB Göttingen opens new communication centre

XLAB Göttingen opens new communication centre

In mid-April 2026, the Göttingen Experimental Laboratory for Young People opened a new community centre with an integrated residential wing for young researchers.

The new building complex expands the existing XLAB Experimental Laboratory on the University of Göttingen campus and facilitates the organisation of multi-day courses, science camps and other educational formats. The project was initiated by the founder and chair of the XLAB Foundation, Professor Eva-Maria Neher. The biochemist has had close ties with the GDNÄ for many years, including serving as its president from 2015 to 2016.

 © Stefan Rampfel

In front of the new XLAB meeting centre (from left): Lower Saxony’s Minister for Science, Falko Mohrs; Göttingen’s Lord Mayor, Petra Broistedt; XLAB founder, Eva-Maria Neher; and University President, Axel Schölmerich.

“With the meeting centre, a long-held wish is becoming a reality,” said Neher at the opening on 15 April 2026, which was attended by Lower Saxony’s Minister for Science, Falko Mohrs, Göttingen’s Lord Mayor, Petra Broistedt, and Axel Schölmerich, the interim President of the University of Göttingen. Schölmerich paid particular tribute to Eva-Maria Neher for her long-standing commitment and the great energy she continually brings to the XLAB and the new guest house.

Up to twelve thousand school students visit the XLAB every year. During events lasting several days, many of them had to rely on hotels or youth hostels, which made it difficult for them to interact with one another. This is set to change in the new meeting centre. Housed in two striking towers, it offers accommodation not only to XLAB guests but also to visiting professors, PhD students and teaching staff. Eva-Maria Neher: “Here, young people can experience science not only in the laboratory, but also through dialogue with one another and with the researchers.”

The project’s origins date back to 2006. Initially, construction costs were estimated at 4.4 million euros; in the end, they amounted to 8.1 million euros. Of this, the federal government and the state of Lower Saxony contributed around six million euros, with the XLAB Foundation covering the remainder.

XLAB is one of Germany’s largest school science laboratories in the STEM field. In the subjects of physics, chemistry, biology, mathematics and computer science, it offers practical experimental courses for school classes, in-depth programmes for particularly interested young people and further training for teachers. For many years, XLAB has successfully promoted dialogue between schools and the scientific community.

Saarbrücken 2018 © Robertus Koppies

© Stefan Rampfel

The new building provides young researchers with a home on Göttingen’s university campus. It is also intended to encourage interaction amongst themselves and with scientists and teaching staff.

Further Information:

Sabine Oertelt-Prigione: “We can learn a great deal from differences”

“We can learn a great deal from differences”

Gender-sensitive medicine? Sabine Oertelt-Prigione explains why it is important for a healthier future at the conference in Bremen – and in this interview.

Professor Oertelt-Prigione, you teach gender-sensitive medicine at Bielefeld University. What exactly does this term mean?
It concerns the influence of gender on health and illness. In my research group in Bielefeld, for example, we investigate whether patients’ gender affects the choice of diagnostic procedures and therapies, and what role it plays in doctor-patient communication. To this end, we analyse international studies and conduct our own surveys. Other groups in gender-sensitive research carry out biomedical laboratory research. We focus more on the clinical and social science aspects of the field. 

Is gender-sensitive medicine the same as gender medicine, or are there differences?
Essentially, these are two different definitions for similar approaches. I myself prefer gender-sensitive medicine because I find it more precise in German. In medicine, we deal with biological and social sex, and their influence. With the term ‘gender medicine’, the focus seems to be more on gender, even though this aspect is researched far less in medicine than biological differences. 

It was not so long ago that scepticism towards gender-sensitive approaches in medicine prevailed. Today, the perception is more positive. Why is that?
One important reason is the improved data. In the 1990s, it was recognised that women are more likely to die from a heart attack because their symptoms do not match the male-dominated textbook description and are therefore frequently overlooked. This finding has since been confirmed by large, long-term studies. Cardiology paved the way for gender-sensitive medicine, but in recent years other fields such as oncology, neurology and infectious diseases have been catching up.

© AG Geschlechtersensible Medzin Bielefeld

This model for gender-sensitive solutions in medical practice was developed by students at Oertelt-Prigione.

Please illustrate this with an example.
Let’s take oncology: cancer drugs often cause more side effects in women. On the other hand, they are sometimes more effective than in men. Checkpoint inhibitors, however, which trigger the body’s own immune system to fight the tumour, often work better in men. 

So gender-sensitive medicine is about more than just women’s health?
Yes, quite clearly. We do not conduct research on women solely for women. In some diseases, men are at a disadvantage; consider osteoporosis or breast cancer, which affects around 700 men in this country every year. In these and other conditions, we are primarily interested in gender-specific differences and the underlying mechanisms. Next, we want to find the appropriate interventions and optimise care. The aim is to learn from these differences in order to improve medicine as a whole. 

What role do societal changes play in the shift in perception of your field of research?
Awareness of the differences between people, of diversity, has grown in recent years. The younger generation in particular is committed to this, and that also benefits us. Added to this has been a shift among funding organisations, which are increasingly recognising and financially supporting our research. 

At the start of the year, the Federal Ministries of Health and Research announced new funding programmes on women’s health. What do you hope to gain from these?
The Federal Ministry of Health’s programme has a total budget of ten million euros and focuses heavily on gynaecological issues such as endometriosis and the menopause.  These topics are fundamentally very important, but somewhat less attractive for my research, partly because the comparison between the sexes plays only a minor role. The Federal Ministry of Research’s programme is more interesting in that regard. The funding pot contains significantly more money for research into new contraceptives, women’s health, but also the gender data gap in clinical trials. The term indicates that many scientific findings are based on studies involving men. It is not uncommon for these findings to be simply applied to women without further scrutiny, which can have fatal consequences. For instance, women react differently to certain active ingredients than men, or they require different dosages. The gender data gap is a topic that particularly interests us in Bielefeld.  

You say the problems have been recognised. How is biomedical research addressing them?
Over the last ten years, much has improved. The guidelines issued by funding bodies at both German and European level have been crucial. Today, funding applications must already specify how researchers intend to address the issue of gender. The gender of study participants must be documented, as must that of laboratory animals. Compared to the past, this is already a huge step forward.

@ Privat

The team led by Sabine Oertelt-Prigione (centre) in front of the OWL Faculty of Medicine at Bielefeld University. @ Private

Are young researchers being trained accordingly?
Gender-sensitive medicine is still scarcely embedded in compulsory teaching; we are awaiting the announced amendment to the Medical Licensing Regulations, which would incorporate the topic and thus make its integration into the curricula necessary. At least many German universities offer relevant optional modules and lecture series. There are now professorships at the Charité, in Magdeburg and here in Bielefeld. At these universities, gender-sensitive medicine is also part of the compulsory curriculum. 

Research is one thing, but do the findings actually make it into practice?
The guidelines issued by professional associations play a major role in this. We have examined many guidelines and found that most are not gender-sensitive. We will be publishing a study on this in the summer. We are also seeking to engage in dialogue with the professional associations. Obstacles here sometimes include a lack of awareness of the issue, but often also a lack of data needed to make guidelines gender-sensitive.  

How did you yourself come across the topic of gender-sensitive medicine?
That was a good twenty years ago during my time as a post-doc in the US. It was rather by chance that I came across the striking gender differences in autoimmune diseases there. I then continued my specialist training in internal medicine and completed a Master’s in Public Health. I actually wanted to become a tropical medicine specialist, but gender-sensitive medicine had really gripped me. I was able to deepen my knowledge at the Charité’s ‘Gender Research in Medicine’ unit, and as a professor in Bielefeld and Nijmegen, I have been able to contribute independently to this field of research for the past ten years.   

Do you already have any ideas for your talk at the GDNÄ conference?
I will provide an overview of the current state of research, but also offer practical suggestions for the doctors in the audience. Incidentally, it is not only human doctors who can benefit from the findings of gender-sensitive research; they are also relevant to veterinary medicine. I am very much looking forward to the exchange in Bremen. 

Michael Droescher © MIKA-fotografie | Berlin

@ Erasmus University Rotterdam

Sabine Oertelt-Prigione giving a talk in Rotterdam.

About the person

Prof. Dr. Sabine Oertelt-Prigione is an internist, holds a Master of Public Health and is a systemic organisational consultant. In 2021, she accepted the appointment to the newly created Chair of Gender-Sensitive Medicine in the Department of Clinical and Theoretical Medicine at Bielefeld University.

 At the same time, she continues to hold the Chair of Gender in Primary and Transmural Care at Radboud University in Nijmegen, the Netherlands, a post she took up in 2017. From 2009 to 2014, Oertelt-Prigione worked as a research fellow at the Charité. In 2015 and 2016, she trained as a systemic organisational consultant at the Artop Institute of Humboldt University in Berlin and qualified as a professor in internal medicine at Charité in 2016.

Sabine Oertelt-Prigione was born in Nuremberg in 1978. She attended the German School in Milan and studied medicine at the University of Milan. As a post-doctoral researcher, she conducted research at the University of California, Davis; she completed her public health studies at the London School of Hygiene and Tropical Medicine.

The physician was a member of the EU Commission’s expert groups on ‘Gendered Innovations’ and ‘Gender and COVID-19’. She is a member of the Medical Committee of the German Science Council and the German Medical Association’s Drug Commission.

Further information:

>> Lecture by Prof. Dr. Sabine Oertelt-Prigione on Sunday, 20 September 2026: “The Significance of Gender in Biomedical Research”

Kai Brüggemann: “There is considerable interest in the GDNÄ”

“There is considerable interest in the GDNÄ”

He is a company director, president of the Industry Club and managing director of the 134th Conference: Kai Brüggemann on Bremen as a business location and why his company plans to start manufacturing in India in the future.

Dr Brüggemann, you have taken on the role of Executive Director for Economic Affairs for the next GDNÄ conference in Bremen in 2026. What appeals to you about this role?
I am impressed by the magnificent history of the Society of German Naturalists and Physicians. It has existed for more than two hundred years and brings together the crème de la crème of the scientific world. What I also like is the interdisciplinary focus and the motto of this year’s conference: ‘Knowledge creates benefits, utilising science’. Science and business should be brought together – that is something Germany urgently needs right now.  

What responsibilities does your GDNÄ role entail?
I would like to raise the profile of this wonderful society a little. Many have never heard of it and are thrilled when they learn about its history and current activities. I noticed this again when I announced the GDNÄ meeting at the Bremen Industry Club. There was great interest and I’m sure quite a few members will be there in the autumn. We could perhaps deepen engagement by holding an information event beforehand, to which the GDNÄ could contribute with a lecture by a renowned scientist on a topical subject. Experience shows that such events attract many members.

@ Industrie-Club Bremen

With the Industry 4.0 Future Workshop, the Industrie-Club Bremen is organising an ideas competition in which young people from Bremen’s universities present their ideas in three-minute pitches. A cash prize will be awarded for the best pitch. All participants will benefit from feedback from experienced entrepreneurs and executives based in Bremen.

You have been President of the Bremen Industry Club since 2019. Could you please give us a brief introduction to it?
We bring together people who are active in Bremen’s business community: entrepreneurs, managers, as well as commercial lawyers and other service providers. We organise events, many of which sell out quickly. Popular formats include training courses such as ‘AI for Executives’, lectures by experts from politics and academia, and the ‘ICB on tour’ series, which takes us to members’ companies. As representatives of the manufacturing sector in Bremen and the surrounding area, we occasionally comment cautiously on political issues.

How is the Bremen economy faring in these turbulent political times?
As a strongly export-oriented, globally networked economy, it is suffering from US tariffs and supply chain disruptions resulting from armed conflicts. This affects practically all key sectors: automotive, aerospace, ports and logistics, and Bremen’s long-established food industry – just think of the coffee roasters. Fundamentally, however, we have a stable economic base here with hidden champions in the SME sector, an increasingly digital focus and interesting start-ups.

You are the managing director of Deharde GmbH, a supplier to the aerospace industry in the Bremen region. How is your company faring?
We plan to expand our existing partnership with a company in India’s Silicon Valley, in Bangalore, and to explore further opportunities for collaboration. In Germany, we can no longer produce high-tech components for customers like Airbus cost-effectively and are suffering from a shortage of skilled workers. That’s not an issue in India. Some of the country’s universities have reached world-class standards and are training large numbers of outstanding engineers. In Germany, by contrast, interest in STEM subjects has been declining for years – that’s going to cause us problems.

You’ve worked in Austria, Switzerland and various places in Germany, but have always kept your home base in Bremen. How did that come about?
It has to do with the family. My wife and children have always said: ‘You can work wherever you want, we’re staying here.’

@ Deharde GmbH

Accompanied by a team from the German Aerospace Centre (DLR), DLR Director General and current GDNÄ President Prof. Anke Kaysser-Pyzalla visited the supplier Deharde GmbH in Varel (the photograph was taken in 2024).

In September, many GDNÄ members will be coming to the meeting in Bremen. What can visitors look forward to?
A city where business and science work well together. A world-class scientific landscape with three renowned universities and the German Research Centre for Artificial Intelligence, the Max Planck Institute for Marine Microbiology and several Fraunhofer Institutes. We are also proud of our free-fall tower for experiments in weightlessness at the Centre for Applied Space Technology and Microgravity at the University of Bremen – the only one of its kind in Europe. Speaking of the university: anyone who still has the image of a red ‘cadet factory’ with questionable scientific standing in mind will be surprised. Our university was first designated a ‘University of Excellence’ in 2012 and is currently reapplying for the title. The science city of Bremen has so many attractions and we look forward to showing them to the GDNÄ.

Michael Droescher © MIKA-fotografie | Berlin

© Privat

Dr Kai Brüggemann, President of the Bremen Industry Club and Economic Director of the 134th Conference of the GDNÄ.

About the person

Dr Kai Brüggemann studied industrial engineering and obtained his doctorate in mechanical engineering. Before taking up his current position as Chairman of the Management Board at Deharde GmbH in Varel, he served as a member of the Executive Board at DB Fernverkehr AG in Frankfurt am Main and as Managing Director of ÖBB Technische Services in Vienna. Prior to that, he spent a total of almost twenty years in senior positions at Airbus in Bremen and Hamburg, interrupted by a two-year stint at the Swiss company RUAG Aerospace. Kai Brüggemann has been a board member of the Industrie-Club Bremen since 2012 and its president since 2019. He will hold the GDNÄ post of Managing Director for Economic Affairs until the 134th meeting of the Natural History Society from 17–20 September 2026.

Michael Droescher © MIKA-fotografie | Berlin

@ Industrie-Club Bremen

Every second Friday in November, the Industrie-Club Bremen invites its members and guests to the traditional Roland Dinner at the Old Town Hall. Here is a glimpse of the banquet hall, with club president Kai Bremen at the lectern.
Further information: